Immunotherapy for mesothelioma

Last medical review:

Immunotherapy helps to strengthen or restore the immune system’s ability to fight cancer. This works to kill cancer cells and stop cancer cells from growing and spreading.

Most people with pleural mesothelioma that can’t be removed with surgery (is unresectable) will be offered immunotherapy. If you have immunotherapy, your healthcare team will use what they know about the cancer and your health to plan the drugs, doses and schedules.

Immunotherapy may be used along with other treatments. You may have immunotherapy to:

  • kill cancer cells
  • stop cancer cells from growing and spreading

Immunotherapy drugs used for mesothelioma

The type of immunotherapy drugs used to treat pleural mesothelioma are called checkpoint inhibitors.

The immune system usually stops itself from attacking normal cells in the body by using specific proteins called checkpoints. Checkpoints slow down or stop an immune system response. Sometimes mesothelioma cells use these checkpoints to hide and avoid being attacked by the immune system. Immune checkpoint inhibitors work by blocking the checkpoint proteins so immune system cells (called T-cells) attack and kill the cancer cells.

The most common checkpoint inhibitors used for mesothelioma are:

  • nivolumab (Opdivo)
  • ipilimumab (Yervoy)
  • pembrolizumab (Keytruda)

A combination of nivolumab and ipilimumab is often used to treat unresectable pleural mesothelioma.

Sometimes checkpoint inhibitors are used with chemotherapy to treat unresectable pleural mesothelioma. Pembrolizumab may be used with cisplatin and pemetrexed.

Side effects

Side effects of immunotherapy will depend mainly on the type of drug or drug combination, the dose, how it’s given and your overall health. Tell your healthcare team if you have side effects that you think might be from immunotherapy. The sooner you tell them of any problems, the sooner they can suggest ways to help you deal with them.

Some common side effects of immunotherapy for unresectable pleural mesothelioma are:

Find out more about immunotherapy

Find out more about immunotherapy. To make the decisions that are right for you, ask your healthcare team questions about immunotherapy.

Details on specific drugs change regularly. Find out more about sources of drug information and where to get details on specific drugs.

Expert review and references

  • John Cho, MD, PhD, FRCPC
  • American Cancer Society. Malignant Mesothelioma. 2018. https://www.cancer.org/.
  • Pass H, Carbone M, Tsao A, Rosenzweig Z. Benign and Malignant Mesothelioma. DeVita VT Jr, Lawrence TS, Rosenberg S. eds. DeVita Hellman and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. Philadelphia, PA: Wolters Kluwer; 2023: Kindle version, [chapter 76], https://read.amazon.ca/?asin=B0BG3DPT4Q&language=en-CA.
  • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Pleural Mesothelioma Version 1.2024. 2024.
  • Nowak AK, Edwards JG, Creaney J. Mesothelioma. Raghavan D, Ahluwalia MS, Blanke CD, et al, eds.. Textbook of Uncommon Cancer. 5th ed. Hoboken, NJ: Wiley Blackwell; 2017: Kindle version (chapter 16) https://read.amazon.ca/?asin=B06XKD44V3&_encoding=UTF8&ref=dbs_p_ebk_r00_pbcb_rnvc00.
  • Bristol-Myers Sqibb Canada Co. Product Monograph: Opdivo. Montréal QC: https://www.bms.com/assets/bms/ca/documents/productmonograph/OPDIVO_EN_PM.pdf.
  • Popat S, Baas P, Faivre-Finn C, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2021: 33(2):129–142.
  • Scherpereel A, Opitz I, Berghmans T, et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. European Respiratory Journal. 2020: 55(6):1–31.

Your trusted source for accurate cancer information

With just $5 from readers like you, we can continue to provide the highest quality cancer information for over 100 types of cancer.

We’re here to ensure easy access to accurate cancer information for you and the millions of people who visit this website every year. But we can’t do it alone.

If everyone reading this gave just $5, we could achieve our goal this month to fund reliable cancer information, compassionate support services and the most promising research. Please give today because every contribution counts. Thank you.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2025 Canadian Cancer Society